Research Evidence / Overview of Studies for Аквамакс
Evidence for Systemic Fluid and Electrolyte Stabilization
This section will summarize the research structure for the intravenous use of Sodium Chloride solution, focusing on studies that examine its role as a fundamental fluid and electrolyte replenisher for managing conditions like hypovolemia and severe hyponatremia. The summary will cover the types of RCTs and observational data that evaluate intravascular volume correction and related physiological biomarkers.
The core evidence for using intravenous Sodium Chloride to support fluid balance is established through extensive regulatory data and routine clinical practice. Since this is a foundational therapy, large-scale studies directly comparing the solution to no treatment are generally not conducted. Instead, research primarily was evaluated in non-inferiority Randomized Controlled Trials (RCTs) exploring how 0.9% saline performs against alternative intravenous fluids, known as "balanced crystalloids," across various critical care and surgical settings.
Studies monitored outcomes related to systemic or functional imbalance, such as the maintenance of fluid volume and the monitoring of physiological strain or stress markers, including renal function. Research explored changes measured during the study period related to key biomarkers like serum chloride and acid-base status. Findings describe patterns observed in the studies where 0.9% saline was observed in research that evaluated fluid volume correction. However, when compared to balanced solutions, some trials reported different patterns related to acid-base markers. These comparative findings were sometimes mixed across different complex patient populations.
What remains uncertain is the long-term comparative effect of 0.9% saline against balanced solutions on major adverse kidney outcomes in general critical care groups, where research is ongoing. Also, evidence derived from settings with varying symptom burdens does not determine whether an individual will respond similarly to a group pattern.
Studies on Acute Symptomatic Hyponatremia Correction
This subsection will detail the research focus on using specific hypertonic Sodium Chloride concentrations to address symptomatic sodium deficits, outlining the primary outcomes measured in these acute-phase studies and the specific patient groups included.
Research on acute symptomatic hyponatremia (very low sodium levels) primarily involves small-scale RCTs and case series focused on using higher-concentration, hypertonic saline solutions. These studies monitored the precise rate of sodium level change and assessed the patient’s neurological status during this critical, short-term correction phase. Research has examined the importance of monitoring the rate of sodium level change, with studies focusing on the risk of complications. Findings describe group patterns related to achieving targeted sodium levels within the initial acute hours of treatment. Follow-up durations were limited to the immediate correction phase, meaning there is limited information for long-term outcomes following this acute intervention.
Evidence for Respiratory Support via Inhalation
This section will outline the body of research, including Randomized Controlled Trials and Systematic Reviews, that have investigated the use of nebulized saline solutions (especially hypertonic) for airway clearance and supportive management in conditions like acute bronchiolitis and chronic airway diseases. The summary will describe the respiratory and length-of-stay outcomes that researchers have primarily examined.
The use of nebulized saline was studied for its role in managing conditions involving periods of heightened symptoms such as acute bronchiolitis in infants and airway clearance in chronic lung conditions. This area is supported by multiple RCTs and Systematic Reviews comparing different saline concentrations. Studies examined outcomes related to physical discomfort and acute changes, such as measurements of respiratory distress scores and the duration of hospital stays (LoS).
Findings describe patterns observed in the studies. Some meta-analyses reported a measured pattern in the length of hospital stay; other studies explored changes in clinical severity scores associated with the use of hypertonic saline in infants with bronchiolitis. However, the evidence for this observation is often graded as having low certainty because the results apply only to the populations studied and the findings were mixed across different trial cohorts. Research on outcomes reflecting daily functioning or activity level over extended periods is generally limited.
Evidence for Localized Symptom Management (Nasal and Ocular)
This section will describe the research base for the non-systemic use of Sodium Chloride solutions as nasal sprays, washes, and eye drops. The summary will focus on studies that measure changes in patient-reported symptom scores (e.g., congestion, dryness) and related functional endpoints like mucociliary clearance time.
Localized applications of saline were evaluated in short-term RCTs and reviews for managing conditions characterized by fluctuating or episodic manifestations like allergic rhinitis and nasal congestion. Research examined patient-reported outcomes describing perceived discomfort by measuring reductions in validated Nasal Symptom Scores. Studies also monitored changes in the rate of mucociliary clearance.
Research explored whether using saline solution was associated with measured changes in patient-reported Nasal Symptom Scores when compared to no intervention. Some studies reported a difference in the measured Mucociliary Clearance time between hypertonic and isotonic saline, but also reported more local irritation in some individuals. Reported observations primarily focused on symptom changes over short-term follow-up periods (e.g., 7 to 14 days).
Long-Term Evidence and Follow-Up in Studies
This section will summarize the duration of observation in the available research, detailing what is known about outcomes tracked over intermediate or extended periods, the durability of reported effects, and areas where evidence is primarily limited to short-term follow-up.
For acute, life-sustaining intravenous uses and respiratory uses in acute illness (such as bronchiolitis), the follow-up durations were limited to the short-term duration of the acute episode or hospital stay. Research has largely explored short-term symptom changes or acute physiological corrections. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes related to the durability of functional status or symptom management over many months or years.
Evidence in Special Populations
This section will describe the existence and focus of research that has specifically evaluated the use of Аквамакс in distinct groups, such as infants with respiratory conditions, children, and patients with specific comorbidities, to highlight where evidence is defined or remains limited.
Specific RCTs was studied for the effects of inhaled hypertonic saline in infants (under 24 months) with acute bronchiolitis, meaning data for this young age group was observed in some studies. However, subgroup findings are uncertain when trying to apply the results to patients with underlying comorbidities. For other special populations, such as older adults with specific comorbidities, the data for certain groups remain insufficient, with most systemic evidence coming from heterogeneous adult critical care populations.
What Remains Uncertain About the Research for Аквамакс
This final section will synthesize the major evidence gaps identified by regulators and systematic reviews, including inconsistent findings across trials, limitations regarding optimal saline concentrations, and areas where more high-quality research is needed to refine current understanding.
Despite the foundational nature of Sodium Chloride solutions, several uncertainties remain in the research landscape. For inhaled and nasal applications, the optimal concentration of the solution to achieve measured changes is still debated, as findings were mixed across various RCTs. Furthermore, the comparative evidence is lacking for many long-term or maintenance protocols. Because results apply only to the populations studied, the extrapolation of acute findings to diverse real-world settings and various comorbid groups requires additional research. Evidence quality varies across studies, particularly in the area of localized symptomatic relief, where some trials have sample sizes that were modest.
